Drug intelligence / Profile preview

Unadol Spasma

Development stage
Unknown
Lead developer
Uni-Pharma Kleon Tsetis
Modality
Small Molecules
Administration
Oral
01

Overview

Unadol Spasma is a fixed-dose combination pharmaceutical product developed and marketed by Uni-Pharma (Syria) for the symptomatic relief of gastrointestinal spasms and associated abdominal pain. It contains paracetamol (acetaminophen), an analgesic and antipyretic, and hyoscine butylbromide (scopolamine butylbromide), a quaternary ammonium antispasmodic agent. Hyoscine butylbromide acts as a competitive antagonist at muscarinic acetylcholine receptors located in the smooth muscle of the gastrointestinal, biliary, and urinary tracts, leading to muscle relaxation and relief from cramping. Paracetamol complements this action by inhibiting prostaglandin synthesis in the central nervous system, thereby elevating the pain threshold. This combination is commonly used for conditions such as irritable bowel syndrome, biliary colic, and renal colic.

Brand names
Unadol Spasma
Other names
Paracetamol/Hyoscine butylbromide
02

Targets

CHRM3 (M3)COX

Beyond the preview

Go deeper on Unadol Spasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unadol Spasma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call